Clinical studies have granted evidence that PDE-5 inhibitors enhance BPH and LUTS symptoms due to the relaxing action of nitric oxide (NO) and the inhibition of prostatic stromal cells proliferation [4,5]. This evidence concerns the gene PDE5A and benign prostatic hyperplasia.